Inhibrx Biosciences (INBX) Competitors $16.28 +0.55 (+3.46%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. AVXL, COGT, CMRX, CDMO, AVBP, SNDX, IMNM, QURE, PHAR, and XERSShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), uniQure (QURE), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Anavex Life Sciences Cogent Biosciences Chimerix Avid Bioservices ArriVent BioPharma Syndax Pharmaceuticals Immunome uniQure Pharming Group Xeris Biopharma Inhibrx Biosciences (NASDAQ:INBX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations. Which has preferable valuation & earnings, INBX or AVXL? Inhibrx Biosciences has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K1,179.03$1.69B$116.750.14Anavex Life SciencesN/AN/A-$43M-$0.55-19.49 Is INBX or AVXL more profitable? Anavex Life Sciences' return on equity of -40.93% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -85.12% -58.90% Anavex Life Sciences N/A -40.93%-36.38% Do institutionals and insiders hold more shares of INBX or AVXL? 82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend INBX or AVXL? Anavex Life Sciences has a consensus target price of $44.00, suggesting a potential upside of 310.45%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media favor INBX or AVXL? In the previous week, Anavex Life Sciences had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Anavex Life Sciences and 2 mentions for Inhibrx Biosciences. Anavex Life Sciences' average media sentiment score of 0.60 beat Inhibrx Biosciences' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, INBX or AVXL? Inhibrx Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. SummaryAnavex Life Sciences beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.85M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio0.1421.5627.4020.24Price / Sales1,179.03274.65418.19125.29Price / Cash0.1341.9536.6357.47Price / Book1.767.518.085.67Net Income$1.69B-$55.05M$3.16B$248.47M7 Day Performance12.86%4.59%2.81%3.29%1 Month Performance25.27%4.86%3.69%5.18%1 Year Performance21.17%5.82%35.30%21.35% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences1.2603 of 5 stars$16.29+3.5%N/A+21.2%$227.85M$200K0.14166AVXLAnavex Life Sciences3.6336 of 5 stars$9.22-2.7%$44.00+377.2%+160.2%$809.33MN/A-16.7640COGTCogent Biosciences2.7921 of 5 stars$7.18+1.1%$14.43+101.0%-8.9%$808.38MN/A-3.9080News CoverageAnalyst RevisionCMRXChimerix0.7488 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.728 of 5 stars$12.50+0.1%$12.25-2.0%+62.3%$799.18M$139.91M-5.23320High Trading VolumeAVBPArriVent BioPharma1.7739 of 5 stars$21.77-5.0%$40.00+83.7%+13.6%$783.81MN/A-5.7740SNDXSyndax Pharmaceuticals2.8502 of 5 stars$9.36+3.5%$35.80+282.5%-53.8%$777.87M$23.68M-2.42110IMNMImmunome2.5536 of 5 stars$9.30+6.0%$23.33+150.9%-28.1%$763.10M$9.04M-2.9240Positive NewsHigh Trading VolumeQUREuniQure2.0001 of 5 stars$13.94+0.6%$37.82+171.3%+270.5%$759.19M$27.12M-3.18500News CoveragePHARPharming Group2.3992 of 5 stars$10.68-2.9%$30.00+181.0%+23.1%$748.58M$297.20M-53.38280Gap DownHigh Trading VolumeXERSXeris Biopharma3.9129 of 5 stars$4.67-0.6%$6.25+33.8%+128.6%$735.01M$222.55M-15.57290Positive News Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Cogent Biosciences Alternatives Chimerix Alternatives Avid Bioservices Alternatives ArriVent BioPharma Alternatives Syndax Pharmaceuticals Alternatives Immunome Alternatives uniQure Alternatives Pharming Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
